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Key questions
What is already known about this subject?
 ► There is a complex interplay between heart failure 
and body composition with neurohormonal activa-
tion and endothelial dysfunction
 ► Cardiac cachexia affects all body composition com-
ponents and is driven by a procatabolic state and is 
a predictor of poor heart failure outcomes.
 ► Cardiac resynchronisation therapy (CRT) causes re-
verse cardiac remodelling improving both morbidity 
and mortality but the impact of CRT on body compo-
sition in these patients is unclear.
What does this study add?
 ► This is the first prospective pilot study to examine 
body composition parameters both before and after 
CRT implantation.
 ► It suggests a trend towards reduction in fat mass in 
CRT non- responders.
 ► The association between left ventricular geometry 
and fat mass relative change following CRT sug-
gests that the increased measured fat mass may be 
linked to reverse cardiac remodelling.
How might this impact on clinic practice?
 ► Successful CRT response appears to be linked to 
maintenance of fat mass status at implant and the 
neurohormonal system appears integral to this.
 ► Knowledge of the relationship of body composition 
and CRT may help better identify those who are like-
ly to benefit from CRT.
AbstrAct
Aims Body composition (BC) is known to alter in heart 
failure. Cardiac resynchronisation therapy (CRT) improves 
left ventricular geometry but the impact on BC is unknown. 
Our aim was to evaluate BC in these patients before and 
after CRT implantation.
Methods Prospective proof- of- concept pilot study of 
heart failure patients undergoing CRT between September 
2014 and December 2015. Assessments performed pre- 
CRT and post- CRT (6 weeks and 6 months) were: BC 
parameters (using air- displacement plethysmography), 
New York Heart Failure classification for assessing 
symptom severity, echocardiography to assess left 
ventricular geometry, electrocardiography, Minnesota Heart 
Failure Questionnaire and N- terminal probrain natriuretic 
peptide (NT- pro- BNP). Repeated measures analysis of 
variance was performed to assess relative change over 
time and potential correlations.
Results Twenty- five patients were recruited; mean- 
age (±SD) was 73.4±10.0 years, 23 males, 18 CRT 
defibrillators (remainder CRT pacemakers), 16 had 
ischaemic aetiology, 6 diabetics, 17 with left bundle- 
branch morphology on ECG and 10 had atrial fibrillation. 
Significant inverse correlations were observed in the 
first 6 weeks following CRT between fat mass and left 
ventricular end- diastolic volume (r=−0.69, p<0.01) and 
NT- pro- BNP and fat mass (r=0.41, p=0.05). No significant 
differences were noted over 6 months. There was an 
observed trend towards reduced fat mass in the first 6 
weeks post- CRT implant driven by non- responders. There 
was no significant difference between responders and 
non- responders in BC over 6 months.
Conclusion This is the first study to observe interplay 
between BC and cardiac geometry/function following CRT; 
a trend in overall fat mass reduction was noted following 
CRT and merits further study.
IntRoduCtIon
There is a complex interplay between heart 
failure (HF), body composition and metab-
olism.1 Development of HF causes neuro-
hormonal activation, a proinflammatory 
state and endothelial dysfunction favouring 
a procatabolic state,2 3 which is heavily influ-
enced by body composition.1 Obesity makes 
development of HF more likely,4 however, 
the presence of adiposity is protective against 
HF progression.5 This observation has been 
termed the ‘obesity paradox’.4 Higher 
adiposity is also inversely related to neurohor-
monal activation.6 Sarcopenia is associated 
with a proinflammatory state7 and increased 
neurohormonal signalling.6 Cardiac cachexia 
affects all body composition components 
and is driven by a procatabolic state; it is a 
predictor of poor HF outcomes.2 4 5 Cardiac 
resynchronisation therapy (CRT) causes 
reverse cardiac remodelling improving both 
morbidity and mortality.8 Cai et al9 observed 
being overweight/obese predicted CRT 
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response and improved 6- month survival suggesting 
body composition may be impacted and/or altered by 
CRT. Baseline body composition parameters may also 
be predictive of CRT response. The aim of our proof- 
of- concept study was to evaluate body composition in 
patients with HF both before and after CRT implantation.
MetHods
Patient population
We performed a prospective pilot study of consecutive 
patients with HF undergoing CRT meeting National Insti-
tute of Clinical Excellence (TA120) implant criteria10 
between September 2014 and December 2015. The study 
was conducted in accordance with the Declaration of 
Helsinki and all patients provided informed consent. Air 
displacement plethysmography (ADP) was performed 
preimplant, 6 weeks and 6 months postimplant. All 
had New York Heart Failure Assessment (NYHA), 6 
min walk test, transthoracic echocardiography, Minne-
sota Living with HF Questionnaire (MLHFQ), resting 
12- lead ECG and blood sampling, including N- terminal 
probrain natriuretic peptide (NT- pro- BNP). All our 
elective implants were performed as same- day proce-
dures as reported previously.11 All underwent echocardi-
ography (Vivid 7, GE Healthcare, Horten, Norway) for 
left ventricular (LV) assessment by a nationally accred-
ited operator on the same machine with measurements 
analysed offline. Whole body ADP (BOD- POD- Life Meas-
urement, Concord, California, USA) reliably and repro-
ducibly measures body composition comparable with 
traditional methods.12 Participants were fasted, rested 
2 hours pretest and had height/weight measurements 
taken. All entered BOD- POD wearing a lycra swim cap 
and underwear only for measurement standardisation; 
two serial measurements were averaged. Where measure-
ments varied significantly a third test was performed. The 
primary outcome was functional response status defined 
as those who survived, did not undergo heart transplanta-
tion and achieved two out of three response criteria (↓>1 
NYHA, ↑>10% 6 MWT distance, ↓MLHFQ score >5) at 
6- month follow- up.
statistical analysis
Statistical analysis was performed using SPSS, V.22.0 
(IBM). Categorical variables were reported as frequency/
percentages. Categorical data were compared using X2/
Fisher’s exact tests. Normally distributed continuous data 
were reported as mean±SD and analysis performed using 
independent t- tests. Non- normally distributed data were 
reported as median (+full range) and compared using 
Mann- Whitney U test. Variation in continuous variables 
over three time periods was analysed using either one- way 
analysis of variance/Friedman test. Mixed between- within 
subjects analysis of variance was used to compare varia-
tion in body composition data in functional responders/
non- responders over 6 months. Pearson (parametric) 
or Spearman’s rank (non- parametric) estimators were 
performed between change in body composition and 
functional/echocardiographic and neurohormonal 
parameters; p<0.05 was considered significant.
Results
Twenty- seven patients were recruited; 25 had baseline 
body composition assessment (one unable to enter BOD- 
POD, one had significant erroneous measurements 
despite repeated attempts). Baseline characteristics are 
shown in table 1. Three patients were unable to have 
6- month body composition assessment (one death during 
follow- up and two not well enough for BOD- POD assess-
ment). The first follow- up was at 1.7 months (SD: 0.3 
months) and final visit was 5.8 months (SD: 0.5 months) 
post- CRT. Baseline characteristics were no different 
between responders versus non- responders, including all 
body composition parameters.
The effect of CRT on cardiac function and body compo-
sition is shown in table 2. There was significant improve-
ment in MLHFQ scores and decrease in QRS duration 
post CRT- implant. Total and percentage fat mass showed 
reduction trend 6 months post- CRT with improvement 
trend in LV ejection fraction) and decrease in LV end- 
systolic volume (LVESV).
Changes over time in body composition for functional 
responders and non- responders were analysed. Online 
supplementary A shows changes in body composition 
after CRT implantation with no difference between 
responders versus non- responders and no change in 
body composition over 6 months. However, a trend for 
higher relative fat mass at baseline for non- responders 
and large decrease 6 weeks post- CRT compared with 
responders was noted. After 6 weeks relative fat mass in 
non- responders returned to levels similar to baseline at 
6 months. Responders had minimal variation over the 
three observation points and had lower relative fat mass 
than non- responders. There was a trend towards differ-
ence between responders and non- responders over time 
for fat mass.
Online supplementary B shows the strongest associa-
tions between body composition and cardiac function 
post- CRT implant. A strong inverse correlation was noted 
between LVESV index and relative fat mass over the first 6 
weeks and medium inverse correlation between fat mass 
and NT- pro- BNP. There was medium association between 
fat mass and estimated glomerular filtration rate (eGFR), 
r=0.41, p=0.06, which trended towards significance at 6 
weeks. Long term, the strongest inverse correlation was 
between fat mass and eGFR. A significant association was 
also observed between eGFR and fat- free mass (r=0.47, 
p=0.04) at 6 months post- CRT implant.
dIsCussIon
This is the first study examining body composition before 
and after CRT implantation in patients with HF and func-
tional response, with association between fat mass and LV 
geometry noted post- CRT implant. Short- term changes in 
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Table 1 Baseline characteristics of the cohort
Total cohort n=25 Responders n=12 Non- responders n=11 P value
Demographics
  Age (years, mean±SD) 73.4±10.0 68.1±14.4 76.0±7.4 0.19
  Male (n,%) 23 (92.0%) 12 (100.0%) 9 (81.8%) 0.42
Device
  CRT- D (n,%) 18 (72.0) 8 (66.7) 9 (81.8) 0.73
  Upgrade (n,%) 9 (36.0) 2 (16.7) 7 (63.6) 0.06
Aetiology
  Ischaemic (n,%) 16 (64.0) 6 (50.0) 8 (72.7) 0.49
  Non- ischaemic (n,%) 9 (36.0) 6 (50.0) 3 (27.3)
Comorbidities
  Diabetes mellitus (n,%) 6 (24.0) 2 (16.7) 4 (36.4) 0.55
  CKD (n,%) 13 (52.0) 7 (58.3) 6 (54.5) 1.00
NYHA (n,%)
  II 10 (43.5) 5 (41.7) 5 (45.5) 0.52
  III 12 (52.2) 7 (58.3) 5 (45.5)
  IV 1 (4.3) 0 (0.0) 1 (9.1)
ECG
  AF (n,%) 9 (36.0) 4 (33.3) 4 (36.4) 1.00
  LBBB (n,%) 17 (68.0) 9 (75.0) 6 (54.5) 0.56
  QRS (ms, median, range) 162(120–212) 168 (138–212) 160 (138–194) 0.60
  6MWT (M, mean±SD) 252.6±132.0 291.9±133.3 215.3±147.4 0.29
  QOL score (median, range) 48.0 (8.0–85.0) 55.5 (9.0–85.0) 29.0 (8.0–68.0) 0.11
Laboratory tests
  eGFR (ml/min/1.73 m2, median, range) 52.0 (25.0–130.0) 52.5 (25.0–130.0) 52.0 (26.0–79.0) 0.61
  NT- pro- BNP (pmol/L, median, range) 267.0 (75.0–4138.0) 237.0 (75.0–4138.0) 273.0 (133.0–547.0) 0.33
Medications
  ACEi/ARB (n,%) 25 (100.0) 12 (100.0) 11 (100.0) 1.00
  BB (n,%) 21 (84.0) 10 (83.3) 10 (90.9) 0.62
  MRA (n,%) 14 (56.0) 7 (58.3) 5 (45.5) 0.38
Echocardiography*
  LVESV (mL, median, range) 125.8 (62.9–268.7) 136.7 (80.7–268.7) 110.9 (62.9–169.4) 0.29
  LVESV_BSA(mL, median, range) 58.9 (38.7–128.0) 66.1 (42.7–128.0) 59.1 (38.7–85.8) 0.35
  LVEF (%, median, range) 25.6 (9.7–35.4) 24.4 (10.0–34.4) 28.6 (9.7–35.4) 0.40
Body composition
  BMI (kg/m2, median, range) 28.7 (22.4–41.9) 29.3 (22.4–37.3) 27.8 (23.9–40.8) 0.85
  FM (kg, median, range) 31.4 (18.1–61.2) 31.3 (19.3–56.4) 29.7 (18.1–58.7) 0.81
  Relative FM (median, range) 0.38 (0.23–0.54) 0.35 (0.28–0.50) 0.42 (0.23–0.54) 0.29
  Lean mass (kg, median, range) 52.3 (30.9–73.3) 52.6 (40.3–73.3) 50.5 (30.9–62.5) 0.48
  Waist (cm, median, range) 98.2 (84.6–131.0) 97.5 (84.6–120.8) 98.2 (85.0–114.5) 0.79
*Based on available data
ACEi, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, ACE receptor antagonist; BMI, body mass index; BNP, brain 
natriuretic peptide; BSA, body surface area; CKD, chronic kidney disease; CRT, cardiac resynchronisation therapy; eGFR, estimated 
glomerular filtration rate; FM, fat mass; LBBB, Left bundle branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular end 
systolic volume; 6MWT, 6 min walk test; NT- pro- BNP, N- terminal probrain natriuretic peptide; NYHA, New York Heart Failure Assessment; 
QOL, quality of life; QRS, QRS width on ECG.
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Table 2 The effect of crt on cardiac function and body composition
Baseline 6 weeks 6 months P value
Clinical, functional, laboratory*
QOL score (median, range) 48.0 (8.0–85.0) 33.5 (0.0–73.0) 23.5 (0.0–0.83) 0.06
QRS (ms, median, range) 162(120–212) 145 (102–194) 159 (112–214) 0.02
6MWT (M, mean±SD) 252.6±132.0 277.1±145.2 242.4±178.8 0.29
eGFR (ml/min/1.73 m2, median, range) 52.0 (25.0–130.0) 47.0 (24.0–105.0) 52.7 (20.0–90.0) 0.34
NT- pro- BNP (pmol/L, median, range) 267.0 (75.0–4138.0) 236.5 (27.0–3848.0) 272.5 (15.0–1690.0) 0.87
Body composition (median, range)
BMI (kg/m2) 28.7 (22.4–41.9) 28.5 (22.0–34.4) 28.0 (22.4–35.7) 0.39
Fat mass (kg)† 31.4 (18.1–61.2) 29.0 (18.9–61.2) 29.1 (18.6–50.3) 0.12
Relative fat mass† 0.38 (0.23–0.54) 0.34 (0.25–0.51) 0.39 (0.28–0.52) 0.09
Lean mass (kg)† 52.3 (30.9–73.3) 53.9 (31.9–75.0) 50.5 (31.9–75.0) 0.19
Waist circumference (cm)† 98.2 (84.6–131.0) 99.3 (76.0–119.4) 100.1 (78.9–120.9) 0.53
Echocardiography‡
LVESV (mL, median, range) 125.8 (62.9–268.7) 112.7 (52.8–210.8) 95.2 (57.8–315.6) 0.26
LVESV_BSA(mL, median, range) 58.9 (38.7–128.0) 56.8 (28.2–118.7) 49.5 (30.6–131.5) 0.26
LVEF (%, median, range) 25.6 (9.7–35.4) 29.4 (13.6–43.6) 32.7 (14.4–41.7) 0.14
*Based on patients able to have clinical, functional and laboratory assessments (baseline=25, 6 weeks=24, 6 months=22),
†Based on participants able/available to have BOD- POD assessment (baseline=25, 6 weeks=23, 6 months=20).
‡Based non complete series of echocardiograms with biplane measurements.
BMI, body mass index; BOD POD, trade name of the device used; BSA, body surface area; eGFR, estimated glomerular filtration rate; 
LVEF, left ventricular ejection fraction ; LVESV, left ventricular end- systolic volume ; 6MWT, 6 min walk test; NT- pro- BNP, N- terminal 
probrain natriuretic peptide; QOL, quality of life.
LVESV/LVESV index were strongly inversely correlated 
with fat- mass and relative fat mass 6 weeks post- CRT. Fat- 
free mass (lean mass) decreased post- CRT, fat mass and 
relative fat mass decreased at first follow- up, returning to 
baseline at 6 months; this trend was driven primarily by 
non- responders.
There are currently no data evaluating reliability of ADP 
in HF.12 ADP interprets body water as fat mass and it is likely 
that the changes noted may be the result of changes in 
body water content. Renal function, specifically eGFR, was 
inversely correlated with change in fat mass at 6 months, 
trending towards significance at 6- week follow- up.
The association between LV geometry and fat mass 
relative change following CRT suggests that the increased 
measured fat mass may be linked to reverse cardiac 
remodelling. The mechanism for this may be multifac-
torial and could be related to changes in body water 
content following CRT. The neurohormonal system may 
be implicated through reduction in circulating natri-
uretic peptides in the presence of increased adiposity.1 3 
Adipocytes are sensitive to natriuretic peptides, activating 
lipolysis and enhancing expression of brown adipocyte 
genes, increasing thermogenesis thereby favouring a 
procatabolic state in progressive HF.3 Naturetic peptides 
are known to stimulate release of adipokines (specifically 
adiponectin and leptin), which increase energy utilisa-
tion and weight reduction.3 Increased NT- pro- BNP imme-
diately after CRT was associated with decreasing fat mass 
supporting the inverse association between natriuretic 
peptides and body mass index (BMI) (BMI/fat mass 
previously reported.3 6 There are limited data on CRT 
and body composition; a retrospective study of 219 CRT 
patients evaluated initial BMI predicting response and 
cardiovascular outcomes at 6 months; they showed over-
weight/obese patients preimplant had better response 
and improved outcomes.9
Deterioration in renal function and presence of stage 3 
chronic kidney disease consistently predicts poor outcomes 
post- CRT.13 Progressive deterioration in eGFR is linked 
to adverse cardiac remodelling.14 The inverse correlation 
between eGFR and fat mass at 6 months suggests increasing 
fat mass is associated with deteriorating renal function 
which is unusual as obesity is believed to preserve renal 
function.4 There was no association between lean mass and 
BMI. Caution is advised interpreting these results as eGFR 
is calculated using the renal disease equation,15 which uses 
body surface area as a parameter, meaning eGFR is not an 
independent variable.
study limitations
Our study has several limitations. Our cohort size was 
small and may impact the findings. However, this was a 
proof- of- concept pilot study and our findings should 
generate further studies in larger cohorts. Two of our 
participants were unable to undergo BOD- POD assess-
ment, which could introduce selection bias. ADP does 
not account for body water and measures it as fat mass, 
meaning patient oedema may impact study findings. Our 
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study was unable to account for the presence of cardiac 
cachexia, which is known to be important in advancing 
HF.1 Also, not all patients were able to have complete LV 
assessment by echocardiography due to body habitus.
ConClusIon
This is the first prospective pilot study to examine body 
composition parameters both before and after CRT 
implantation. It suggests a trend towards reduction in fat 
mass in CRT non- responders. Successful CRT response 
appears to be linked to maintenance of fat mass status at 
implant. The neurohormonal system appears integral to 
this.
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